117 related articles for article (PubMed ID: 228313)
1. Mechanism of the protective effect of angiotensin-converting enzyme inhibition in hemorrhagic shock.
Trachte GJ; Lefer AM
Proc Soc Exp Biol Med; 1979 Oct; 162(1):54-7. PubMed ID: 228313
[No Abstract] [Full Text] [Related]
2. Prostacyclin mediates the potentiated hypotensive effect of bradykinin following captopril treatment.
Mullane KM; Moncada S
Eur J Pharmacol; 1980 Sep; 66(4):355-65. PubMed ID: 6998710
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of captopril on regional haemodynamic responses to angiotensin I and bradykinin in conscious rats.
Gardiner SM; Kemp PA; Bennett T
Br J Pharmacol; 1993 Mar; 108(3):769-75. PubMed ID: 8467363
[TBL] [Abstract][Full Text] [Related]
4. Effects of SQ 20881 and captopril on mesenteric, renal, and iliac vasculatures.
Fiksen-Olsen MJ; Britton SL; Houck PC; Romero JC
Am J Physiol; 1983 Mar; 244(3):H313-9. PubMed ID: 6187226
[TBL] [Abstract][Full Text] [Related]
5. Captopril and the intestinal response to hemorrhagic shock.
Rosenfeld LM; Cooper HS
Arch Int Pharmacodyn Ther; 1982 Sep; 259(1):144-52. PubMed ID: 6758718
[TBL] [Abstract][Full Text] [Related]
6. Effects of angiotensin I converting enzyme inhibitor (SQ 14225) on control of aldosterone.
Eguchi T; Saito I; Nakamura R; Yasui T; Saruta T
Acta Endocrinol (Copenh); 1980 Jun; 94(2):213-20. PubMed ID: 6251687
[No Abstract] [Full Text] [Related]
7. Converting enzyme inhibition and modulation of plasma renin activity with captopril in anesthetized rats.
Suzuki M; Satoh S
Arch Int Pharmacodyn Ther; 1981 Sep; 253(1):121-36. PubMed ID: 6275810
[TBL] [Abstract][Full Text] [Related]
8. Effect of captopril on the blood pressure response to angiotensin I in turkeys.
Fregly MJ; Simpson CF; Palmore WP
Proc Soc Exp Biol Med; 1981 Jan; 166(1):35-8. PubMed ID: 6258174
[No Abstract] [Full Text] [Related]
9. Inhibition of central angiotensin I conversion by oral captopril.
Marson O; Ribeiro AB; Tufik S; Kohlmann O; Ramos OL
Braz J Med Biol Res; 1981 Apr; 14(1):73-6. PubMed ID: 6272920
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421.
Cohen ML; Kurz KD
J Pharmacol Exp Ther; 1982 Jan; 220(1):63-9. PubMed ID: 6273529
[No Abstract] [Full Text] [Related]
11. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
[TBL] [Abstract][Full Text] [Related]
12. Anti-shock actions of a new converting enzyme inhibitor, enalaprilic acid, in hemorrhagic shock in cats.
Freeman JG; Hock CE; Edmonds JS; Lefer AM
J Pharmacol Exp Ther; 1984 Dec; 231(3):610-5. PubMed ID: 6094795
[TBL] [Abstract][Full Text] [Related]
13. Role of extrarenal and intrarenal converting enzyme inhibition in renal vasodilator response to intravenous captopril.
Wong PC; Zimmerman BG
Life Sci; 1980 Oct; 27(14):1291-7. PubMed ID: 6255273
[No Abstract] [Full Text] [Related]
14. Comparison in normal volunteers of three converting enzyme inhibitors: RHC 3659, MK 421 and captopril.
Burnier M; Biollaz J; Brunner HR; Turini GA; Gavras H
Am J Cardiol; 1982 Apr; 49(6):1550-1. PubMed ID: 6280484
[No Abstract] [Full Text] [Related]
15. Comparison of angiotensin converting enzyme inhibitors captopril and MK421-diacid in guinea pig atria.
Nakashima A; Angus JA; Johnston CI
Eur J Pharmacol; 1982 Jul; 81(3):487-92. PubMed ID: 6288415
[TBL] [Abstract][Full Text] [Related]
16. Dissociation between in vivo and in vitro measurements of converting enzyme activity after chronic oral treatment with captopril in rats.
Unger T; Hübner D; Schüll B; Yukimura T; Rascher W; Lang RE; Ganten D
Am J Cardiol; 1982 Apr; 49(6):1530-2. PubMed ID: 6280482
[TBL] [Abstract][Full Text] [Related]
17. Captopril attenuates adrenergic vasoconstriction in rat mesenteric arteries by angiotensin-dependent and -independent mechanisms.
Collis MG; Keddie JR
Clin Sci (Lond); 1981 Sep; 61(3):281-6. PubMed ID: 7021045
[TBL] [Abstract][Full Text] [Related]
18. [A new point of attack for the treatment of hypertension; captopril, an orally active inhibitor of the enzymatic conversion of angiotensin I into angiotensin II].
Schalekamp MA; de Bruyn JH; Wenting GJ; Man in 't Veld AJ; Derkx FH
Ned Tijdschr Geneeskd; 1980 Nov; 124(47):1996-2003. PubMed ID: 6255350
[No Abstract] [Full Text] [Related]
19. Inhibition of angiotesin-converting enzyme by quercetin alters the vascular response to brandykinin and angiotensin I.
Häckl LP; Cuttle G; Dovichi SS; Lima-Landman MT; Nicolau M
Pharmacology; 2002 Aug; 65(4):182-6. PubMed ID: 12174832
[TBL] [Abstract][Full Text] [Related]
20. Converting enzyme inhibition during chronic angiotensin II infusion in rats. Evidence against a nonangiotensin mechanism.
Textor SC; Brunner HR; Gavras H
Hypertension; 1981; 3(2):269-76. PubMed ID: 6260647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
